Saulo Mendoza-Ramírez
Department of Surgical Pathology, ABC Observatory Medical Center, Mexico City, MexicoPublications
-
Research Article
Expression of PDL1 and P53 in Muscle-Invasive Bladder Carcinoma: A New Alternative for Neoadjuvant Treatment in Urothelial Cancer
Author(s): Karen Sarahí Vázquez-Rodrígue, Lázaro A Ramírez-Balderrama, Luis Jonathan Bueno-Rosario, Saulo Mendoza-Ramírez, Marco Antonio Olvera-Olvera and Mario Murguia-Perez*
Invasive Urothelial Carcinoma (IUC) is the tenth most common malignancy worldwide. Its treatment depends on the clinical stage in which it is found and based on this; there are various therapeutic options to use. Currently, immunotherapy plays a key role in the treatment of several malignant tumors, including IUC. Our work identified the expression of PD-L1 in Muscle-Invasive Bladder Carcinoma (MIBC), a field little explored at present, using a validated clone of PD-L1 (28-8, BioSB®), finding CPS>5% of PD-L1 in 35% (11/30 specimens) of MIBC cases; in addition, there was a correlation between the expression of PD-L1 with the presence of mononuclear infiltrate (p=0.002). Overexpression of p53 was also identified (60%, 18/30 specimens), but no statistical significance was found in the correlation with various variables evalua.. Read More»